ERBB2 and breast carcinoma: Similar to the group of Dillon et al., they revealed AKT1 as the main isoform mediating the positive effect on tumor initiation and progression in ErbB-2- and PyMT-mediated breast cancer mice, whereas AKT2 has no effect on tumor initiation.